EU industry: new PV fee plan better, but still much room for improvement
This article was originally published in Scrip
Executive Summary
Groups representing the innovator and generic pharmaceutical industries in Europe have welcomed the changes made by the European Commission to its original plans for a pharmacovigilance fee system, but say that there are still major problems with the proposal.